What's Happening?
A real-world study has found that the anti-amyloid therapy Leqembi (lecanemab) helps most patients with early Alzheimer's disease remain clinically stable over 17 months. The study, presented at the Alzheimer's Association International Conference 2026,
reported that 75.9% of participants remained at the same disease stage, while 6.6% improved by one stage. The findings suggest that Leqembi is effective in everyday clinical settings, with a safety profile consistent with previous trials. The study highlights the potential of Leqembi to preserve cognitive function and quality of life for Alzheimer's patients.
Why It's Important?
The study's findings are significant as they provide evidence of Leqembi's effectiveness in real-world clinical settings, beyond controlled clinical trials. This is crucial for understanding how the drug performs across diverse patient populations with varying health conditions. The ability to maintain clinical stability is vital for Alzheimer's patients, as it allows them to preserve cognitive function and independence. The study also reinforces the importance of real-world evidence in complementing clinical trial data, helping clinicians make informed decisions about treatment options for Alzheimer's disease.
